CY1114315T1 - Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα - Google Patents

Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα

Info

Publication number
CY1114315T1
CY1114315T1 CY20131100167T CY131100167T CY1114315T1 CY 1114315 T1 CY1114315 T1 CY 1114315T1 CY 20131100167 T CY20131100167 T CY 20131100167T CY 131100167 T CY131100167 T CY 131100167T CY 1114315 T1 CY1114315 T1 CY 1114315T1
Authority
CY
Cyprus
Prior art keywords
vaccination
excipients
limited
multiple dosage
dosage influenza
Prior art date
Application number
CY20131100167T
Other languages
Greek (el)
English (en)
Inventor
Giudice Giuseppe Del
Riccardo Manetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114315(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1114315T1 publication Critical patent/CY1114315T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CY20131100167T 2006-06-15 2013-02-25 Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα CY1114315T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81466506P 2006-06-15 2006-06-15
EP07804945A EP2032163B1 (en) 2006-06-15 2007-06-15 Adjuvant-sparing multi-dose influenza vaccination regimen

Publications (1)

Publication Number Publication Date
CY1114315T1 true CY1114315T1 (el) 2016-08-31

Family

ID=38832174

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100167T CY1114315T1 (el) 2006-06-15 2013-02-25 Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα

Country Status (17)

Country Link
US (3) US20090220545A1 (enExample)
EP (1) EP2032163B1 (enExample)
JP (2) JP5566687B2 (enExample)
KR (1) KR20090016704A (enExample)
CN (1) CN101500603A (enExample)
AU (1) AU2007258874B2 (enExample)
BR (1) BRPI0713150A8 (enExample)
CA (1) CA2657989A1 (enExample)
CY (1) CY1114315T1 (enExample)
DK (1) DK2032163T3 (enExample)
EA (1) EA017441B1 (enExample)
ES (1) ES2401484T3 (enExample)
PL (1) PL2032163T3 (enExample)
PT (1) PT2032163E (enExample)
SI (1) SI2032163T1 (enExample)
WO (1) WO2007144772A2 (enExample)
ZA (1) ZA200810582B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EA201071086A1 (ru) * 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR101176305B1 (ko) * 2009-10-14 2012-08-23 웅진코웨이주식회사 붉나무 추출물을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
US20130101609A1 (en) * 2010-01-24 2013-04-25 Novartis Ag Irradiated biodegradable polymer microparticles
US8852157B2 (en) 2010-02-21 2014-10-07 Innovative Bottles, Llc Disposable items made from bioplastic resins
CN102232042B (zh) * 2010-02-21 2015-01-14 创新瓶业有限责任公司 生物可降解药房容器以及安全盖
WO2011141443A1 (en) * 2010-05-11 2011-11-17 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
TR201811280T4 (tr) * 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
CA2955456A1 (en) 2014-07-17 2016-01-21 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
US20180133375A1 (en) * 2014-10-30 2018-05-17 Chugai Seiyaku Kabushiki Kaisha Pre-Filled Syringe Formulation With Needle, Which Is Equipped With Syringe Cap
JP6813492B2 (ja) 2015-02-03 2021-01-13 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素充填済み容器
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
JP2018527286A (ja) * 2015-07-17 2018-09-20 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN118976103A (zh) 2017-12-18 2024-11-19 英特维特国际股份有限公司 猪甲型流感病毒疫苗
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241926A (en) * 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
WO1990001948A1 (en) 1988-08-25 1990-03-08 The Liposome Company, Inc. Influenza vaccine and novel adjuvants
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
PE20061428A1 (es) * 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
US20100158943A1 (en) * 2005-11-04 2010-06-24 Novartis Vaccines And Diagnostics Srl Administration routes for priming/boosting with influenza vaccines
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.

Also Published As

Publication number Publication date
DK2032163T3 (da) 2013-03-25
JP5981951B2 (ja) 2016-08-31
BRPI0713150A2 (pt) 2012-03-27
WO2007144772A2 (en) 2007-12-21
CN101500603A (zh) 2009-08-05
AU2007258874B2 (en) 2013-11-14
EA017441B1 (ru) 2012-12-28
EP2032163B1 (en) 2013-01-23
EP2032163A2 (en) 2009-03-11
JP5566687B2 (ja) 2014-08-06
ZA200810582B (en) 2009-09-30
HK1129205A1 (en) 2009-11-20
PT2032163E (pt) 2013-04-11
US9901630B2 (en) 2018-02-27
CA2657989A1 (en) 2007-12-21
JP2014098038A (ja) 2014-05-29
US20090220545A1 (en) 2009-09-03
US8808686B2 (en) 2014-08-19
WO2007144772A3 (en) 2008-03-27
KR20090016704A (ko) 2009-02-17
SI2032163T1 (sl) 2013-05-31
ES2401484T3 (es) 2013-04-22
BRPI0713150A8 (pt) 2017-08-22
AU2007258874A1 (en) 2007-12-21
EA200970013A1 (ru) 2009-06-30
US20140370053A1 (en) 2014-12-18
US20120039934A1 (en) 2012-02-16
PL2032163T3 (pl) 2013-06-28
JP2009539965A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
CY1114315T1 (el) Εμβολιασμος γριπης με αγωγη πολλαπλων δοσεων με περιορισμενα εκδοχα
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
NZ585674A (en) Vaccination with multiple clades of h5 influenza a virus
CY1111553T1 (el) Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση
CL2021003019S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
WO2008096831A1 (ja) 癌の治療剤
GT200200138A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
BRPI0716518B8 (pt) vacina de ipv e uso da mesma
CR11307A (es) Vacunas
DE60142615D1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
CY1107302T1 (el) Χρηση ρεσβερατρολης για την παρασκευη ενος φαρμακου που ειναι χρησιμο για τη θεραπεια λοιμωξεων απο τον ιο της γριπης
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
NO20065480L (no) Vaksiner.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
AR119159A1 (es) Tratamientos de angioedema
CL2025000520A1 (es) Paradigma de tratamiento para una terapia con anticuerpos anti-cd19.
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico
EA201170569A1 (ru) Лекарственное средство для повышения дозы противоаллергической вакцины
MX2022007305A (es) Mejoras en la administracion sin aguja.
AR052392A1 (es) Mutantes de la proteina n del virus del sindrome reproductor y respiratorio de los porcinos
MA42317B2 (fr) Composition de vaccin combinée pour administration multiple